Kim et al. reported paradoxically higher MET uptake in grade 2 and 3 gliomas with IDH1 mutations and 1p/19q codeletions compared to IDH1-wildtype astrocytomas [19]. The gene discussed is IDH1; the disease is central nervous system cancer.